Fulcher Jennifer A, Chang Margaret H, Wang Shuo, Almazan Tim, Hashimi Sara T, Eriksson Anna U, Wen Xiangshu, Pang Mabel, Baum Linda G, Singh Ram Raj, Lee Benhur
Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California 90095, USA.
J Biol Chem. 2009 Sep 25;284(39):26860-70. doi: 10.1074/jbc.M109.037507. Epub 2009 Jul 27.
Galectin-1 is a galactoside-binding lectin expressed in multiple tissues that has pleiotropic immunomodulatory functions. We previously showed that galectin-1 activates human monocyte-derived dendritic cells (MDDCs) and triggers a specific genetic program that up-regulates DC migration through the extracellular matrix, an integral property of mucosal DCs. Here, we identify the galectin-1 receptors on MDDCs and immediate downstream effectors of galectin-1-induced MDDC activation and migration. Galectin-1 binding to surface CD43 and CD45 on MDDCs induced an unusual unipolar co-clustering of these receptors and activates a dose-dependent calcium flux that is abrogated by lactose. Using a kinome screen and a systems biology approach, we identified Syk and protein kinase C tyrosine kinases as mediators of the DC activation effects of galectin-1. Galectin-1, but not lipopolysaccharide, stimulated Syk phosphorylation and recruitment of phosphorylated Syk to the CD43 and CD45 co-cluster on MDDCs. Inhibitors of Syk and protein kinase C signaling abrogated galectin-1-induced DC activation as monitored by interleukin-6 production; and MMP-1, -10, and -12 gene up-regulation; and enhanced migration through the extracellular matrix. The latter two are specific features of galectin-1-activated DCs. Interestingly, we also found that galectin-1 can prime DCs to respond more quickly to low dose lipopolysaccharide stimulation. Finally, we underscore the biological relevance of galectin-1-enhanced DC migration by showing that intradermal injection of galectin-1 in MRL-fas mice, which have a defect in skin DC emigration, increased the in vivo migration of dermal DCs to draining lymph nodes.
半乳糖凝集素-1是一种在多种组织中表达的半乳糖苷结合凝集素,具有多效性免疫调节功能。我们之前表明,半乳糖凝集素-1可激活人单核细胞衍生的树突状细胞(MDDC),并触发特定的基因程序,上调DC通过细胞外基质的迁移,这是黏膜DC的一个重要特性。在这里,我们鉴定了MDDC上的半乳糖凝集素-1受体以及半乳糖凝集素-1诱导的MDDC激活和迁移的直接下游效应器。半乳糖凝集素-1与MDDC表面的CD43和CD45结合,诱导这些受体形成异常的单极共聚集,并激活乳糖可消除的剂量依赖性钙流。通过激酶组筛选和系统生物学方法,我们确定Syk和蛋白激酶C酪氨酸激酶是半乳糖凝集素-1对DC激活作用的介质。半乳糖凝集素-1而非脂多糖刺激Syk磷酸化,并使磷酸化的Syk募集到MDDC上的CD43和CD45共聚集处。Syk和蛋白激酶C信号抑制剂可消除半乳糖凝集素-1诱导的DC激活,这通过白细胞介素-6的产生、基质金属蛋白酶-1、-10和-12基因上调以及通过细胞外基质的迁移增强来监测;后两者是半乳糖凝集素-1激活的DC的特异性特征。有趣的是,我们还发现半乳糖凝集素-1可使DC对低剂量脂多糖刺激的反应更快。最后,我们通过在皮肤DC迁移存在缺陷的MRL-fas小鼠皮内注射半乳糖凝集素-1,增加真皮DC向引流淋巴结的体内迁移,强调了半乳糖凝集素-1增强DC迁移在生物学上的相关性。